Treatment developments on the horizon

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Yeah, so in the future there's actually many more kind of exciting treatments that are coming. I think they really, in my mind, fall into two different classes that I would consider. One is talking about new medications. So for instance, there's a number of new classes of medicines that are being evaluated. So, one would be IL-6 inhibitors, tyrosine kinase inhibitors, tie2 agonists, and additional complement cascade inhibitors for dry macular degeneration. So, a really robust pipeline, I think. I always like to say we have a number of horses in the race. We're not sure which one's gonna win, but I think patients win when there are multiple targets in mind. And then, there are also new delivery approaches. And so, that's gonna be the other class that we kind of really look at. And I think the one that I'm most excited about is the gene therapy end of the spectrum. And that can be delivered in multiple ways. So, that could be delivered subretinally, suprachoroidally, or as an intravitreal injection. A number of trials are ongoing. In fact, some of the subretinal trials really are at the phase three stage. And so, these are large final trials before the FDA reviews the data. And the data really does look encouraging. So, a lot to look forward to.